Trial Profile
A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CAP-1002 (Primary)
- Indications Cardiomyopathies; Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms HOPE-1; HOPE-DUCHENNE
- Sponsors Capricor
- 24 Jan 2019 According to a Capricor Therapeutics media release, results of this study were published in the 23rd Jan 2019, online issue of Neurology, the medical journal of the American Academy of Neurology.
- 24 Jan 2019 Results presented in a Capricor Therapeutics media release.
- 18 Jul 2018 Status changed from active, no longer recruiting to completed.